Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger and BTB domain containing 45 pseudogene 2 (ZBTB45P2) is classified as a **pseudogene**, meaning it is a genomic DNA sequence similar to a protein-coding gene (in this case, to ZBTB45), but is considered non-functional and does not produce a functional protein[6][1][3]. There is no evidence ZBTB45P2 acts as a therapeutic target, receptor, enzyme, transporter, or has an active biological role. Pseudogenes may sometimes regulate the expression of related protein-coding genes through RNA-based mechanisms such as transcriptional interference or acting as microRNA decoys, but there is no current evidence or report that ZBTB45P2 performs any such regulatory function[6][2]. As a result, ZBTB45P2 is not listed as a disease marker, drug target, or actionable biomolecule[6][1][3][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger and BTB domain containing 45 pseudogene 2 (ZBTB45P2).